| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dementia | 14 | 2021 | 123 | 5.540 |
Why?
|
| Pneumonia | 6 | 2017 | 49 | 2.560 |
Why?
|
| Atrial Fibrillation | 13 | 2016 | 172 | 2.200 |
Why?
|
| Analgesics, Opioid | 9 | 2020 | 246 | 2.030 |
Why?
|
| Antidepressive Agents | 9 | 2022 | 142 | 2.020 |
Why?
|
| Metformin | 5 | 2020 | 50 | 1.940 |
Why?
|
| Electronic Health Records | 6 | 2020 | 707 | 1.750 |
Why?
|
| Female | 69 | 2022 | 12444 | 1.740 |
Why?
|
| Humans | 78 | 2022 | 17376 | 1.680 |
Why?
|
| Algorithms | 6 | 2020 | 226 | 1.580 |
Why?
|
| Aged | 44 | 2022 | 6129 | 1.450 |
Why?
|
| Aged, 80 and over | 30 | 2021 | 1942 | 1.440 |
Why?
|
| Sulfonylurea Compounds | 3 | 2019 | 25 | 1.390 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2022 | 39 | 1.380 |
Why?
|
| Hypertension | 6 | 2021 | 469 | 1.310 |
Why?
|
| Male | 48 | 2021 | 9843 | 1.310 |
Why?
|
| Risk Assessment | 15 | 2021 | 1079 | 1.270 |
Why?
|
| Community-Acquired Infections | 6 | 2016 | 20 | 1.250 |
Why?
|
| Alzheimer Disease | 7 | 2018 | 49 | 1.250 |
Why?
|
| Hypoglycemic Agents | 4 | 2020 | 251 | 1.210 |
Why?
|
| Databases, Factual | 9 | 2022 | 306 | 1.190 |
Why?
|
| Retrospective Studies | 19 | 2022 | 2428 | 1.190 |
Why?
|
| Pregnancy Outcome | 6 | 2022 | 158 | 1.180 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2021 | 120 | 1.160 |
Why?
|
| Pregnancy | 23 | 2022 | 1466 | 1.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2021 | 84 | 1.150 |
Why?
|
| Diabetes, Gestational | 4 | 2019 | 312 | 1.080 |
Why?
|
| Washington | 13 | 2019 | 385 | 1.000 |
Why?
|
| United States | 22 | 2021 | 3891 | 0.990 |
Why?
|
| Brain | 2 | 2017 | 48 | 0.930 |
Why?
|
| Risk Factors | 24 | 2020 | 3255 | 0.910 |
Why?
|
| Medical Record Linkage | 3 | 2014 | 37 | 0.890 |
Why?
|
| Benzodiazepines | 4 | 2022 | 28 | 0.860 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2022 | 34 | 0.860 |
Why?
|
| Chronic Pain | 4 | 2017 | 127 | 0.810 |
Why?
|
| Middle Aged | 32 | 2021 | 7885 | 0.800 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 666 | 0.800 |
Why?
|
| Young Adult | 23 | 2021 | 2473 | 0.780 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2020 | 22 | 0.780 |
Why?
|
| Labetalol | 1 | 2022 | 9 | 0.770 |
Why?
|
| Adult | 31 | 2020 | 7529 | 0.750 |
Why?
|
| Incidence | 13 | 2021 | 1266 | 0.730 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 53 | 0.710 |
Why?
|
| Cognition Disorders | 3 | 2016 | 30 | 0.700 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 54 | 0.700 |
Why?
|
| Cohort Studies | 17 | 2021 | 2526 | 0.690 |
Why?
|
| Premature Birth | 1 | 2022 | 132 | 0.690 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 1 | 0.680 |
Why?
|
| Autopsy | 3 | 2018 | 16 | 0.680 |
Why?
|
| Vitamins | 1 | 2020 | 59 | 0.650 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 64 | 0.650 |
Why?
|
| Case-Control Studies | 13 | 2016 | 1100 | 0.640 |
Why?
|
| Early Diagnosis | 1 | 2019 | 36 | 0.640 |
Why?
|
| Infant, Newborn | 13 | 2022 | 805 | 0.630 |
Why?
|
| Pharmacoepidemiology | 5 | 2021 | 18 | 0.630 |
Why?
|
| Cognition | 2 | 2020 | 81 | 0.610 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 455 | 0.610 |
Why?
|
| Antiemetics | 1 | 2018 | 4 | 0.610 |
Why?
|
| Morning Sickness | 1 | 2018 | 4 | 0.610 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 86 | 0.610 |
Why?
|
| Comorbidity | 8 | 2021 | 564 | 0.600 |
Why?
|
| Cholinergic Antagonists | 2 | 2015 | 7 | 0.590 |
Why?
|
| Labor, Induced | 2 | 2014 | 6 | 0.570 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 702 | 0.560 |
Why?
|
| Prescription Drug Misuse | 1 | 2017 | 9 | 0.550 |
Why?
|
| Decision Making | 1 | 2018 | 172 | 0.540 |
Why?
|
| Opioid-Related Disorders | 2 | 2017 | 174 | 0.540 |
Why?
|
| Drug Prescriptions | 6 | 2020 | 148 | 0.530 |
Why?
|
| Insulin | 1 | 2017 | 190 | 0.520 |
Why?
|
| Prospective Studies | 14 | 2020 | 1229 | 0.520 |
Why?
|
| Anesthesia, Local | 1 | 2016 | 3 | 0.510 |
Why?
|
| Anesthesia, General | 1 | 2016 | 2 | 0.510 |
Why?
|
| Antihypertensive Agents | 4 | 2022 | 155 | 0.490 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 380 | 0.490 |
Why?
|
| Adolescent | 18 | 2021 | 3533 | 0.490 |
Why?
|
| Histamine H2 Antagonists | 3 | 2011 | 13 | 0.490 |
Why?
|
| Prevalence | 11 | 2017 | 839 | 0.490 |
Why?
|
| Prescription Drugs | 1 | 2015 | 31 | 0.470 |
Why?
|
| Medical Records | 2 | 2014 | 93 | 0.470 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2020 | 128 | 0.470 |
Why?
|
| Pain | 1 | 2015 | 75 | 0.470 |
Why?
|
| Infant Welfare | 1 | 2014 | 4 | 0.460 |
Why?
|
| Maternal Welfare | 1 | 2014 | 12 | 0.460 |
Why?
|
| Depression | 1 | 2019 | 487 | 0.460 |
Why?
|
| Blood Glucose | 3 | 2019 | 315 | 0.460 |
Why?
|
| Qualitative Research | 3 | 2021 | 262 | 0.430 |
Why?
|
| Insurance Coverage | 1 | 2014 | 103 | 0.430 |
Why?
|
| Women's Health | 1 | 2014 | 197 | 0.420 |
Why?
|
| Time Factors | 8 | 2020 | 1044 | 0.420 |
Why?
|
| Logistic Models | 8 | 2018 | 884 | 0.420 |
Why?
|
| Diabetes Complications | 2 | 2012 | 106 | 0.420 |
Why?
|
| Perinatal Care | 1 | 2013 | 12 | 0.410 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 70 | 0.400 |
Why?
|
| Lisinopril | 1 | 2012 | 4 | 0.400 |
Why?
|
| Natural Language Processing | 1 | 2013 | 60 | 0.380 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 11 | 0.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 165 | 0.370 |
Why?
|
| Age Factors | 4 | 2019 | 884 | 0.370 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 15 | 0.370 |
Why?
|
| Drug Interactions | 5 | 2022 | 17 | 0.360 |
Why?
|
| Stroke | 6 | 2015 | 310 | 0.360 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 100 | 0.350 |
Why?
|
| Pneumonia, Viral | 1 | 2011 | 57 | 0.340 |
Why?
|
| Wounds and Injuries | 2 | 2021 | 44 | 0.340 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 24 | 0.330 |
Why?
|
| Body Mass Index | 3 | 2012 | 937 | 0.330 |
Why?
|
| Risk | 8 | 2020 | 498 | 0.320 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 5 | 0.320 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2020 | 537 | 0.300 |
Why?
|
| Probiotics | 1 | 2008 | 4 | 0.300 |
Why?
|
| Drug Utilization Review | 3 | 2013 | 24 | 0.300 |
Why?
|
| Emergency Service, Hospital | 3 | 2022 | 381 | 0.290 |
Why?
|
| Gastrointestinal Tract | 1 | 2008 | 7 | 0.290 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2008 | 7 | 0.290 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 439 | 0.290 |
Why?
|
| Influenza, Human | 1 | 2011 | 282 | 0.290 |
Why?
|
| Focus Groups | 2 | 2018 | 144 | 0.280 |
Why?
|
| Risk Reduction Behavior | 3 | 2017 | 104 | 0.280 |
Why?
|
| Population Surveillance | 7 | 2016 | 254 | 0.270 |
Why?
|
| Immunocompetence | 3 | 2012 | 10 | 0.270 |
Why?
|
| Odds Ratio | 4 | 2011 | 644 | 0.270 |
Why?
|
| Infant | 4 | 2022 | 1162 | 0.270 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2015 | 168 | 0.260 |
Why?
|
| Body Size | 1 | 2006 | 31 | 0.260 |
Why?
|
| Prognosis | 2 | 2019 | 604 | 0.250 |
Why?
|
| Predictive Value of Tests | 5 | 2013 | 342 | 0.250 |
Why?
|
| Birth Certificates | 4 | 2013 | 24 | 0.250 |
Why?
|
| Geriatric Assessment | 2 | 2016 | 43 | 0.250 |
Why?
|
| Quality of Life | 2 | 2021 | 505 | 0.250 |
Why?
|
| Prehypertension | 2 | 2016 | 21 | 0.240 |
Why?
|
| Blood Pressure | 3 | 2016 | 275 | 0.240 |
Why?
|
| Glycated Hemoglobin A | 2 | 2020 | 184 | 0.230 |
Why?
|
| International Classification of Diseases | 4 | 2013 | 86 | 0.230 |
Why?
|
| Obesity | 2 | 2012 | 814 | 0.230 |
Why?
|
| Drug Utilization | 3 | 2015 | 122 | 0.220 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 1287 | 0.210 |
Why?
|
| Treatment Outcome | 3 | 2020 | 1170 | 0.210 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2015 | 15 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 311 | 0.210 |
Why?
|
| Hospitalization | 2 | 2021 | 805 | 0.210 |
Why?
|
| Anticonvulsants | 2 | 2013 | 9 | 0.200 |
Why?
|
| Tramadol | 1 | 2022 | 1 | 0.200 |
Why?
|
| Radiography | 2 | 2013 | 36 | 0.200 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2013 | 93 | 0.200 |
Why?
|
| Accidental Falls | 2 | 2020 | 46 | 0.200 |
Why?
|
| Methyldopa | 1 | 2022 | 6 | 0.200 |
Why?
|
| Nifedipine | 1 | 2022 | 7 | 0.200 |
Why?
|
| Muscles | 1 | 2022 | 3 | 0.190 |
Why?
|
| Carcinoma | 1 | 2002 | 22 | 0.190 |
Why?
|
| Psychotropic Drugs | 1 | 2002 | 34 | 0.190 |
Why?
|
| Brain Ischemia | 2 | 2013 | 37 | 0.190 |
Why?
|
| Glucose Tolerance Test | 2 | 2019 | 107 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 1155 | 0.180 |
Why?
|
| Myocardial Infarction | 3 | 2015 | 225 | 0.180 |
Why?
|
| Bayes Theorem | 4 | 2022 | 73 | 0.180 |
Why?
|
| Down-Regulation | 1 | 2021 | 14 | 0.180 |
Why?
|
| Ovarian Neoplasms | 1 | 2002 | 52 | 0.180 |
Why?
|
| Drug Monitoring | 1 | 2021 | 18 | 0.180 |
Why?
|
| Continental Population Groups | 2 | 2013 | 289 | 0.180 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 4 | 0.170 |
Why?
|
| Social Behavior | 1 | 2020 | 21 | 0.170 |
Why?
|
| Caregivers | 1 | 2021 | 130 | 0.170 |
Why?
|
| Central Nervous System Agents | 1 | 2020 | 5 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2018 | 211 | 0.170 |
Why?
|
| Veterans Health | 1 | 2020 | 16 | 0.170 |
Why?
|
| Health Resources | 1 | 2020 | 34 | 0.170 |
Why?
|
| Independent Living | 1 | 2020 | 24 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 538 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2015 | 1287 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 31 | 0.160 |
Why?
|
| Datasets as Topic | 1 | 2019 | 20 | 0.160 |
Why?
|
| Hospitals, Veterans | 1 | 2019 | 31 | 0.160 |
Why?
|
| Biomarkers | 1 | 2020 | 306 | 0.150 |
Why?
|
| Ondansetron | 1 | 2018 | 3 | 0.150 |
Why?
|
| Pregnancy Trimester, First | 2 | 2015 | 41 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 609 | 0.150 |
Why?
|
| Cerebral Cortex | 1 | 2018 | 2 | 0.140 |
Why?
|
| tau Proteins | 1 | 2018 | 4 | 0.140 |
Why?
|
| Amyloid beta-Peptides | 1 | 2018 | 4 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2018 | 28 | 0.140 |
Why?
|
| Analgesics | 1 | 2018 | 27 | 0.140 |
Why?
|
| Veterans | 1 | 2019 | 145 | 0.140 |
Why?
|
| Sex Factors | 1 | 2019 | 607 | 0.140 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 480 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 311 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2019 | 239 | 0.130 |
Why?
|
| Accidents, Traffic | 1 | 2016 | 15 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2015 | 44 | 0.130 |
Why?
|
| Pregnancy Complications | 3 | 2013 | 197 | 0.130 |
Why?
|
| Gestational Age | 2 | 2016 | 112 | 0.130 |
Why?
|
| African Americans | 1 | 2019 | 443 | 0.130 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2016 | 54 | 0.130 |
Why?
|
| Patient Participation | 1 | 2017 | 123 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2010 | 231 | 0.130 |
Why?
|
| Anti-Anxiety Agents | 1 | 2016 | 5 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2016 | 45 | 0.130 |
Why?
|
| Osteoporotic Fractures | 1 | 2016 | 41 | 0.120 |
Why?
|
| Trimethoprim | 1 | 2015 | 4 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2015 | 15 | 0.120 |
Why?
|
| Insulin, Long-Acting | 1 | 2015 | 11 | 0.120 |
Why?
|
| Social Support | 1 | 2017 | 208 | 0.120 |
Why?
|
| Eclampsia | 1 | 2015 | 12 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 107 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2015 | 40 | 0.120 |
Why?
|
| Child | 4 | 2016 | 2382 | 0.120 |
Why?
|
| Obstetric Labor Complications | 1 | 2014 | 12 | 0.110 |
Why?
|
| Health Surveys | 2 | 2015 | 250 | 0.110 |
Why?
|
| Mass Screening | 1 | 2020 | 671 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 300 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2017 | 253 | 0.110 |
Why?
|
| Mothers | 1 | 2014 | 103 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 22 | 0.110 |
Why?
|
| Elective Surgical Procedures | 1 | 2013 | 10 | 0.110 |
Why?
|
| Cesarean Section | 1 | 2013 | 33 | 0.110 |
Why?
|
| Data Mining | 1 | 2013 | 16 | 0.100 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2013 | 86 | 0.100 |
Why?
|
| Valproic Acid | 1 | 2013 | 3 | 0.100 |
Why?
|
| Drugs, Generic | 1 | 2013 | 4 | 0.100 |
Why?
|
| Longitudinal Studies | 4 | 2016 | 677 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2014 | 100 | 0.100 |
Why?
|
| Maternal Exposure | 1 | 2013 | 66 | 0.100 |
Why?
|
| Delivery, Obstetric | 1 | 2013 | 18 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 145 | 0.100 |
Why?
|
| Prescriptions | 1 | 2013 | 29 | 0.100 |
Why?
|
| Epilepsy | 1 | 2012 | 13 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2014 | 190 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 11 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2013 | 76 | 0.100 |
Why?
|
| Antipsychotic Agents | 1 | 2013 | 49 | 0.100 |
Why?
|
| Neoplasms | 1 | 2017 | 448 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2013 | 128 | 0.100 |
Why?
|
| Health Services Research | 1 | 2013 | 212 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2014 | 151 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2012 | 75 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 26 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 395 | 0.090 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 64 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2012 | 175 | 0.090 |
Why?
|
| Calcium Channel Blockers | 1 | 2010 | 15 | 0.090 |
Why?
|
| Seizures | 1 | 2010 | 28 | 0.090 |
Why?
|
| Emergency Medical Services | 2 | 2021 | 48 | 0.090 |
Why?
|
| Anti-Ulcer Agents | 1 | 2010 | 5 | 0.090 |
Why?
|
| Asthma | 1 | 2013 | 388 | 0.090 |
Why?
|
| Probability | 1 | 2010 | 72 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 533 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2010 | 46 | 0.080 |
Why?
|
| Ethnic Groups | 1 | 2013 | 456 | 0.080 |
Why?
|
| Ischemic Attack, Transient | 1 | 2009 | 27 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2009 | 8 | 0.080 |
Why?
|
| Child, Preschool | 1 | 2013 | 1375 | 0.080 |
Why?
|
| Age Distribution | 2 | 2015 | 239 | 0.070 |
Why?
|
| Leisure Activities | 1 | 2007 | 34 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 44 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 316 | 0.070 |
Why?
|
| Cimetidine | 1 | 2006 | 2 | 0.070 |
Why?
|
| Aspirin | 1 | 2007 | 63 | 0.060 |
Why?
|
| Warfarin | 1 | 2007 | 73 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2007 | 127 | 0.060 |
Why?
|
| Research Design | 1 | 2008 | 343 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2007 | 152 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2016 | 38 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 263 | 0.050 |
Why?
|
| Aripiprazole | 1 | 2022 | 5 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 144 | 0.050 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2013 | 17 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 86 | 0.050 |
Why?
|
| Exercise | 1 | 2007 | 513 | 0.050 |
Why?
|
| Rats | 1 | 2021 | 35 | 0.040 |
Why?
|
| Informatics | 1 | 2020 | 2 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 280 | 0.040 |
Why?
|
| Health Maintenance Organizations | 2 | 2013 | 408 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 154 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 58 | 0.030 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2016 | 25 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 85 | 0.030 |
Why?
|
| Essential Hypertension | 1 | 2016 | 1 | 0.030 |
Why?
|
| Longevity | 1 | 2016 | 12 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2016 | 72 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 82 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 83 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2015 | 21 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 253 | 0.030 |
Why?
|
| Histamine H1 Antagonists | 1 | 2015 | 3 | 0.030 |
Why?
|
| Muscarinic Antagonists | 1 | 2015 | 5 | 0.030 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2015 | 8 | 0.030 |
Why?
|
| Pain Management | 1 | 2015 | 53 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2015 | 13 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 180 | 0.030 |
Why?
|
| Medicare | 1 | 2016 | 201 | 0.030 |
Why?
|
| Weight Gain | 1 | 2016 | 156 | 0.030 |
Why?
|
| Telephone | 1 | 2015 | 150 | 0.030 |
Why?
|
| Perineum | 1 | 2013 | 2 | 0.030 |
Why?
|
| Perinatal Mortality | 1 | 2013 | 3 | 0.030 |
Why?
|
| Term Birth | 1 | 2013 | 9 | 0.030 |
Why?
|
| Maternal Age | 1 | 2014 | 74 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 81 | 0.030 |
Why?
|
| Luria-Nebraska Neuropsychological Battery | 1 | 2013 | 1 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 38 | 0.030 |
Why?
|
| Pregnancy, Multiple | 1 | 2013 | 4 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2013 | 11 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2013 | 26 | 0.030 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2013 | 18 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 108 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 96 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 90 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2013 | 94 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 165 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 218 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 32 | 0.020 |
Why?
|
| Data Collection | 1 | 2012 | 240 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 109 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 215 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2013 | 127 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2010 | 24 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 405 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2015 | 729 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2007 | 55 | 0.020 |
Why?
|
| California | 1 | 2013 | 2317 | 0.020 |
Why?
|